In a report released today, Robert Driscoll from Wedbush maintained a Buy rating on Tyra Bioscience (TYRA – Research Report), with a price target of $27.00. The company’s shares closed yesterday at $13.90.
Driscoll covers the Healthcare sector, focusing on stocks such as Kura Oncology, Arvinas Holding Company, and IGM Biosciences. According to TipRanks, Driscoll has an average return of -4.2% and a 38.22% success rate on recommended stocks.
In addition to Wedbush, Tyra Bioscience also received a Buy from H.C. Wainwright’s Mitchell Kapoor in a report issued on December 26. However, on December 22, Bank of America Securities maintained a Hold rating on Tyra Bioscience (NASDAQ: TYRA).
See Insiders’ Hot Stocks on TipRanks >>
TYRA market cap is currently $598.5M and has a P/E ratio of -9.99.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tyra Bioscience (TYRA) Company Description:
Tyra Biosciences Inc is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
Read More on TYRA:
- Tyra Biosciences doses first patient with TYRA-200
- Tyra Biosciences downgraded to Neutral from Buy at BofA
- Tyra Biosciences price target lowered to $19 from $20 at H.C. Wainwright
- Tyra Biosciences reports Q3 EPS (49c), consensus (35c)
- Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
